Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-response antiviral strategy study after nucleos(t)ide analogue combination therapy in chronic hepatitis B
ChiCTR-ONRC-12001921Phase 4Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of lamivudine, adefovir dipivoxil and telbivudine in Chronic Hepatitis B (CHB) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Sustained biochemical response, Sustained virological response and 1 more. Started Jan 2011; status: completed.
02
Drugs
lamivudineadefovir dipivoxiltelbivudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR-ONRC-12001921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONRC-12001921.